

Type:
DUR Meeting

State:
FL

Classes:
Monoclonal Antibody

Date:
Thursday, March 22, 2018

Venue:
AHCA Headquarters Complex Bldg 3

Address:
2727 Mahan Dr

Room:
Conf Room A

State Contacts / Committee In Attendance?

Notes

Members

Moses Allen, Pharm. D.

X

Diane Fagan, R.Ph.

X

Larry Field, D.O.

X

Venessa Goodnow, Pharm.D.


X

Anna Hayden, D.O.

X


Jeffrey Martorana, M.D.

X



ARTIA
SOLUTIONS
consult guide connect

| | |
|------------------------|---|
| Kevin Olson, Pharm.D. | X |
| Alfred Romay, Pharm.D. | X |
| Luis Saez, D.O. | X |
| Amy Zitiello, D.O. | |



| My Market Basket | Marketshare | Current Status | PDL Meeting Result | Notes |
|------------------|-------------|--------------------|---------------------------|-------|
| Synagis | 100% | Class Not Reviewed | Motion to change criteria | |

Additional Notes:

Makala Burkhart, Magellan DUR Pharmacist presented. Other Magellan PharmD- Elboni Moore, Stephanie McGriff. MME Edits: 90, effecting 3/26/18. Top 3 abuse deterrent opioids after Auto PA imposed: Embeda, Fentanyl, Morphine ER. SPinraza and Exondys are driving the Misc Class in overall spending, Magellan will tease out specific drugs next meeting. Topics: 1. PPIs, 2. 2017 Asthma (GINA) Guidelines- treatment and geographical trends, FL does spacers thru DME and could include on fee schedules for MM plans to provide through pharmacy. 3. Hep C criteria. 4. LAI utilization- 51.7% non-compliant, USF polypharmacy criteria- tabled for more info from USF. 5. MME>500. 6. Opiates and Benzo overlap. 7. Top 10 prescribers. 8. Meds to treat Tardive Dyskinesia. Quarterly activities: 1. Influenza. 2. Synagis utilization: FFS 48% <1 yo, 52% 1-2, 0% 2-3. MCO 78% <1, 21% 1-2, 0.5% 2-3. Criteria was proposed to mirror the 2014 guidelines (remove the 29-34 GA treatment group. The committee pediatrician was not there to comment on the changes, and Moses Allen pointed that out. Question was brought up about possible legal action if a patient meets the indication on the label, but they deny treatment. Topic of changing the criteria was discussed at length and a motion was made to go w/ the AAP guidelines. Vote 4-2, 2 abstained. Speakers were then called up. 2 speakers

passionately expressed their concerns with changing the Synagis criteria. Someone on the committee then tried to make another motion to push the decision to June, but one committee member had already left and they lost the quorum and could not vote on the motion. Other topics- DME denials: top denial 'services covered by HMO. Topics for next meeting: ADHD diagnosis, Suboxone max dose.

